Interactive Brokers Launches Trading on Cboe Europe Derivatives (CEDX)
12.6.2024 17:00:00 EEST | Business Wire | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global electronic broker, today announced the addition of European stock options and European index futures and options through Cboe Europe Derivatives (CEDX). This addition allows Interactive Brokers' clients another means to trade European equity derivatives alongside a broad range of global financial instruments, including stocks, options, futures, currencies, bonds, funds and more, from a single unified platform.
Adding access to CEDX complements Interactive Brokers’ existing European equity derivatives offering through Eurex and Euronextand gives clients an additional way to manage European investments. With CEDX, Interactive Brokers' clients can trade over 300 stock options on leading European companies from 14 countries and European equity index derivatives. Futures and options contracts based on Cboe Europe single country and pan-European indices are available on well-known benchmarks, including Cboe Eurozone 50, Cboe Germany 40 and Cboe UK 100. In addition, CEDX’s exchange, market data and connectivity fees are waived until the end of 2024.
Milan Galik, Chief Executive Officer of Interactive Brokers, stated, “The introduction of Cboe Europe Derivatives underscores our commitment to providing clients with an extensive range of products to enhance their trading strategies at low cost. As investors increasingly use derivatives to diversify and fine-tune market exposure, CEDX broadens the investment options available for our clients.”
Iouri Saroukhanov, Head of European Derivatives, Cboe Europe, added, “We’re thrilled that clients of Interactive Brokers can now access Cboe Europe Derivatives’ suite of pan-European equity derivatives contracts. This is a significant milestone in CEDX’s journey to improve the ability of retail investors to gain access to and benefit from European derivatives, particularly options.”
For more information on CEDX European stock options and equity index derivatives at Interactive Brokers, please visit:
US - Cboe Europe Derivatives (CEDX) (US and other countries served by IB LLC)
Canada - Cboe Europe Derivatives (CEDX)
United Kingdom - Cboe Europe Derivatives (CEDX)
Europe - Cboe Europe Derivatives (CEDX)
Hong Kong - Cboe Europe Derivatives (CEDX)
Singapore - Cboe Europe Derivatives (CEDX)
Australia - Cboe Europe Derivatives (CEDX)
Japan - Cboe Europe Derivatives (CEDX)
The Best Informed Investors Choose Interactive Brokers
About Interactive Brokers Group, Inc.:
Interactive Brokers Group affiliates provide automated trade execution and custody of securities, commodities, and foreign exchange around the clock on over 150 markets in numerous countries and currencies, from a single unified platform to clients worldwide. We serve individual investors, hedge funds, proprietary trading groups, financial advisors and introducing brokers. Our four decades of focus on technology and automation has enabled us to equip our clients with a uniquely sophisticated platform to manage their investment portfolios. We strive to provide our clients with advantageous execution prices and trading, risk and portfolio management tools, research facilities and investment products, all at low or no cost, positioning them to achieve superior returns on investments. Interactive Brokers has consistently earned recognition as a top broker, garnering multiple awards and accolades from respected industry sources such as Barron’s, Investopedia, Stockbrokers.com, and many others.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240611475625/en/
Contacts
Contact for Interactive Brokers Group, Inc. Media: Katherine Ewert,
media@ibkr.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enhertu ® Approved in the EU as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer27.10.2026 09:30:00 EET | Press release
Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. In DESTINY-Breast05, Enhertu significantly reduced the risk of in
Avanzanite Bioscience Expands UK Presence and Appoints Sarah O’Connell as Country Manager27.10.2026 09:00:00 EET | Press release
Avanzanite Bioscience B.V., a European pharmaceutical company focused on rare diseases, today announced the expansion of its United Kingdom (UK) presence and the appointment of Sarah O’Connell as UK Country Manager. The move strengthens Avanzanite’s long-term commitment to the UK and its ability to help eligible patients access innovative rare disease medicines. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261027035012/en/ Sarah O'Connell, Country Manager, UK, Avanzanite Bioscience “The UK is essential to our ambition of building Avanzanite into a European rare disease champion. We feel a deep and lasting connection to this market and there is no European reach without the UK,” said Adam Plich, co-founder and CEO, Avanzanite Bioscience. “At a time when parts of the life sciences sector are reassessing their investment and presence in the UK, we are choosing to commit and build for the long term. With Sarah’s extensive rare
LTM Secures Strategic Engagement with a Global Banking and Financial Services Firm27.10.2026 06:30:00 EET | Press release
LTM, the Business Creativity partner to the world's largest enterprises, has secured a strategic engagement with a large global banking and financial services firm, further strengthening its position as a trusted technology and transformation partner to leading financial institutions. This two-year engagement is already underway with an option to extend for an additional year and has a potential value of up to USD 100 million. The engagement reflects the continued expansion of LTM’s relationship with the client and its growing role in advancing strategic technology programmes and supporting supplier consolidation initiatives across the organization. Under the agreement, LTM will serve as a preferred partner driving the consolidation and delivery of strategic technology requirements across key wealth, personal banking, and global functions. The engagement will leverage LTM’s deep banking-domain expertise, engineering excellence, and global delivery capabilities to support the client’s t
DDN Selected to Modernize Research Data Infrastructure at UNSW Sydney26.10.2026 23:30:00 EET | Press release
DDN, the global leader in AI and data intelligence solutions, today announced that UNSW Sydney has selected DDN to deliver a new research data storage environment as part of the university’s Research Data Experience (RDE) program. Working with Australian software company Arcitecta, DDN will combine its EXAScaler parallel file system with Arcitecta’s Mediaflux® data management platform to help researchers spend less time managing data and more time using it. Following an extensive 18-month evaluation, UNSW selected an integrated approach that will replace 11 legacy storage systems with a coordinated environment for high-performance storage and enterprise data management. The decision reflects a broader challenge facing research-intensive institutions: how to support rapidly expanding scientific datasets while simplifying infrastructure, improving data accessibility and managing long-term costs. Built for data-intensive research, high-performance computing and AI workloads, DDN EXAScaler
Agent Assurance by TestMu AI Is Now Generally Available, Letting Teams Test What Their AI Agents Actually Change26.10.2026 17:15:00 EET | Press release
TestMu AI (formerly LambdaTest), the world's first Agentic AI-powered Quality Engineering platform, today announced the general availability of Agent Assurance. Agent Assurance tests AI agents that take actions, such as calling tools, writing files, and changing records, by checking what a run actually changed rather than what the agent says it did. Any team can now create a TestMu AI account and run it against its own agent without booking a demo first. Agent Assurance launched on August 17, 2026, behind a waitlist and a guided onboarding session. Since then, Rook, the CLI that runs Agent Assurance, has shipped a steady run of releases, shaped by feedback from early teams. Agent evaluation has mostly graded the final reply, and that reply can be wrong about the agent's own work. In CXBench, a benchmark of LLM agents in regulated customer-experience workflows published in October 2026, 80.1% of runs that reached the right outcome still failed the process checks, and only 13.8% passed b
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom